Cargando…
Ziv-aflibercept in metastatic colorectal cancer
The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental gro...
Autores principales: | Patel, Anuj, Sun, Weijing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869833/ https://www.ncbi.nlm.nih.gov/pubmed/24368879 http://dx.doi.org/10.2147/BTT.S39360 |
Ejemplares similares
-
Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013) -
Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015) -
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020) -
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016) -
Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016)